MBX Biosciences, Inc./$MBX
1D1W1MYTD1Y5YMAX
Capital at risk
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
- Ticker
- $MBX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- Carmel, United States
- Website
- mbxbio.com
MBX Metrics
BasicAdvanced
$3B
-
-$2.41
-
-
Price and volume
Market cap
$3B
52-week high
$72.64
52-week low
$9.64
Average daily volume
427K
Financial strength
Current ratio
18.084
Quick ratio
17.82
Long term debt to equity
0.007
Total debt to equity
0.008
Profitability
EBITDA (TTM)
-117.664
Management effectiveness
Return on assets (TTM)
-22.08%
Return on equity (TTM)
-33.17%
Valuation
Price to book
7.21
Price to tangible book (TTM)
7.21
Price to free cash flow (TTM)
-31.336
Free cash flow yield (TTM)
-3.19%
Free cash flow per share (TTM)
-1.965
Growth
Earnings per share change (TTM)
-16.49%
Upcoming events
No upcoming events
Funds containing MBX
AllUSDGBPEUR
Fund name | Fund size | $MBX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.20% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.20% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.